10.6微米红外激光辅助治疗糖尿病周围神经病变:双盲随机对照试验研究方案
本研究为双盲、随机、假激光对照试验方案,计划招募114例糖尿病周围神经病变患者,按1:1随机分为10.6微米激光艾灸组或假激光组,两组均接受中西医基础治疗,共12次治疗、每周3次、持续4周。主要结局为神经传导速度,次要结局包括密歇根神经病变筛查量表评分、糖尿病特异性生活质量评分、血液流变学参数及安全性与盲法评估。
要点
- 10.6微米激光艾灸波长接近传统艾灸红外辐射峰及人体穴位,产热相似但无烟无味。
- 计划招募114例糖尿病周围神经病变患者,1:1随机分入激光艾灸组或假激光组。
- 两组均接受中西医基础治疗,共12次治疗、每周3次、持续4周,主要结局为神经传导速度。
核心结论
- 本研究旨在比较10.6微米激光艾灸与假激光艾灸联合药物治疗的疗效,激光艾灸可能缓解症状、改善生活质量、减少药物用量并避免严重副作用。
研究设计与样本
- 随机、双盲、假激光对照试验方案,计划招募114例符合纳入和排除标准的糖尿病周围神经病变患者,按1:1分配至激光艾灸组或假激光组。
主要发现
- 两组均接受中西医基础综合治疗,并接受共12次真或假激光艾灸治疗,持续4周、每周3次。
- 主要结局为神经传导速度,次要结局包括密歇根神经病变筛查量表评分、糖尿病特异性生活质量评分、血液流变学参数及安全性和盲法评估。
- 结局指标在基线、治疗后2周、激光艾灸治疗结束(4周)及治疗结束后4、8周(即第8、12周)采集。
关键数值与推荐
- 传统艾灸已被推荐作为常规医学治疗的辅助疗法用于治疗糖尿病周围神经病变,以加速缓解症状。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic neurological complication. It is the main cause of disability in diabetes mellitus (DM) patients and seriously affects the quality of life of patients. Pharmacological treatments always associate with limited efficacy and adverse effects. Moxibustion has been recommended to treat DPN as an adjuvant therapy to conventional medical treatment to accelerate alleviation of the symptoms of DPN. 10.6-μm laser moxibustion (LM), whose wavelength is close to the peak of infrared radiation spectrum of the traditional moxibustion as well as human acupoints, produces the thermal effect similar with moxibustion but with no smoke or smell. The purpose of this sham controlled clinical trial is to determine the effect and safety of 10.6-μm LM as adjuvant therapy in patients with DPN. METHODS: This is a protocol for a randomized, double-blind, sham-controlled trial. One hundred fourteen patients meeting the inclusion and exclusion criteria will be recruited and randomly assigned to the LM group or the sham LM group with a 1:1 allocation ratio. Patients in both groups will receive a basic integrated treatment of Chinese and Western medicine and a total of 12 sessions of true or sham LM treatments over 4 weeks with 3 sessions a week. The primary outcome is nerve conduction velocity (NCV), and the secondary outcomes include Michigan Neuropathy Screening Instrument (MNSI) scores, Diabetes-Specific Quality of Life (DSQL) scores, blood rheology parameters, and assessments of safety and blinding. Outcome measures will be collected at baseline, 2 weeks after treatment, the end of LM treatments (4 weeks), and 4, 8 weeks after the end of LM treatment (8, 12weeks). DISCUSSION: This study will be conducted to compare the efficacy of LM versus sham LM combined with medical treatment. 10.6-μm LM may alleviate symptoms, improve quality of life, and reduce the dosage of drugs as well as avoid causing serious side effects. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000029329 . Registered on 25 January 2020.
引用
- Lin L, Chen Y, Li Y, et al. 10.6-μm infrared laser as adjuvant therapy for diabetic peripheral neuropathy: study protocol for a double-blind, randomized controlled trial. Trials. 2022. PMID: 35042552. doi:10.1186/s13063-021-05901-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。